Headlands Technologies LLC Invests $1.58 Million in VanEck Biotech ETF $BBH

Headlands Technologies LLC purchased a new stake in VanEck Biotech ETF (NASDAQ:BBH) during the 2nd quarter, HoldingsChannel reports. The fund purchased 7,754 shares of the company’s stock, valued at approximately $1,576,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BBH. Empowered Funds LLC acquired a new stake in shares of VanEck Biotech ETF in the 4th quarter valued at $38,000. Allworth Financial LP increased its position in VanEck Biotech ETF by 255.0% in the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after purchasing an additional 306 shares during the period. Fifth Third Bancorp bought a new stake in shares of VanEck Biotech ETF during the 1st quarter valued at $127,000. Huntington National Bank acquired a new position in VanEck Biotech ETF in the fourth quarter valued at about $132,000. Finally, Evelyn Partners Asset Management Ltd boosted its stake in VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock worth $178,000 after acquiring an additional 136 shares during the last quarter. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Trading Down 0.4%

Shares of BBH opened at $235.50 on Tuesday. VanEck Biotech ETF has a 52-week low of $160.91 and a 52-week high of $244.35. The stock has a 50 day simple moving average of $213.87 and a 200 day simple moving average of $197.38.

Insider Buying and Selling at VanEck Biotech ETF

In other news, major shareholder Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock in a transaction dated Wednesday, July 15th. The shares were sold at an average price of $16.71, for a total value of $109,166.43. Following the completion of the transaction, the insider owned 3,552,710 shares of the company’s stock, valued at $59,365,784.10. This trade represents a 0.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 10,493 shares of company stock worth $175,335.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.